Karolina A. Aberg, PhD; Youfang Liu, PhD; Jozsef Bukszár, PhD; et al.
free access
has multimedia
JAMA Psychiatry. 2013;70(6):573-581. doi:10.1001/jamapsychiatry.2013.288
Aberg et al sought to identify the specific genetic variants and pathways that increase susceptibility to schizophrenia in an effort to improve understanding of the molecular and biological mechanisms involved with the disease. See also the editorial by Hardy.
-
Editorial
Psychiatric Genetics: Are We There Yet?
John Hardy, PhD
JAMA Psychiatry
Andrew E. Timms, PhD; Michael O. Dorschner, PhD; Jeremy Wechsler, MS; et al.
free access
JAMA Psychiatry. 2013;70(6):582-590. doi:10.1001/jamapsychiatry.2013.1195
Timms et al identify new genetic factors strongly predisposing to schizophrenia in families with multiple affected individuals with schizophrenia.
Radhika Kandaswamy, MSc, MPhil, PhD; Andrew McQuillin, PhD; Sally I. Sharp, PhD; et al.
free access
JAMA Psychiatry. 2013;70(6):591-598. doi:10.1001/jamapsychiatry.2013.38
Kandaswamy et al examined genetic markers at the gene encoding the metabotropic glutamate receptor 3 to evaluate the allelic association with bipolar disorder.
Kenneth S. Kendler, MD; Steven H. Aggen, PhD; Michael C. Neale, PhD
free access
JAMA Psychiatry. 2013;70(6):599-607. doi:10.1001/jamapsychiatry.2013.751
Kendler et al determine the structure of genetic and environmental risk factors for the 9 DSM-IV symptomatic MD criteria.
Mohammed R. Milad, PhD; Sharon C. Furtak, PhD; Jennifer L. Greenberg, PsyD; et al.
free access
JAMA Psychiatry. 2013;70(6):608-618. doi:10.1001/jamapsychiatry.2013.914
Milad and colleagues conducted a cross-sectional, case-control, functional magnetic resonance imaging study examining the psychophysiological and neurobiological correlates of conditioned fear extinction in patients with obsessive-compulsive disorder (OCD).
Jan C. Beucke, MS; Jorge Sepulcre, MD, PhD; Tanveer Talukdar, MS; et al.
free access
JAMA Psychiatry. 2013;70(6):619-629. doi:10.1001/jamapsychiatry.2013.173
Beucke et al determined regions of abnormal degree connectivity in 46 patients with obsessive-compulsive disorder (OCD) to investigate whether connectivity measures are affected by antidepressant medication in this population.
Eugene C. Somoza, MD, PhD; Douglas Winship, BS; Charles W. Gorodetzky, MD, PhD; et al.
free access
JAMA Psychiatry. 2013;70(6):630-637. doi:10.1001/jamapsychiatry.2013.872
To evaluate the efficacy of vigabatrin to treat cocaine dependence, Somoza et al performed a 12-week trial among 186 treatment seekers, with follow-up visits at weeks 13, 16, 20, and 24. Participants received vigabatrin (3.0 g/d) or matched placebo, plus cognitive behavioral therapy and individual counseling for 13 weeks. See Editorial by Silverman.
-
Editorial
The Potential Value of a Negative Finding: An Illustrative Example
Kenneth Silverman, PhD; Anthony DeFulio, PhD; Jeannie-Marie Leoutsakos, PhD
JAMA Psychiatry
Jean Decety, PhD; Laurie R. Skelly, PhD; Kent A. Kiehl, PhD
free access
JAMA Psychiatry. 2013;70(6):638-645. doi:10.1001/jamapsychiatry.2013.27
Decety et al evaluated the differences in patterns of neural activity in 80 incarcerated individuals with psychopathy and incarcerated persons serving as controls during the perception of empathy-eliciting stimuli depicting other people experiencing pain.